Why Madrigal Pharmaceuticals Just Hit Investors’ Radar
Madrigal Pharmaceuticals (MDGL) moved into focus after reporting third quarter 2026 results, shifting to net income of US$55.44 million compared with a net loss of US$114.19 million a year earlier.
The sharp swing to quarterly profit has not stopped Madrigal Pharmaceuticals’ share price from coming under pressure, with a 30 day share price return of down 13.67% and a year to date share price return of down 27.40% at about US$431.16. That pullback comes against a much stronger long run picture. The 1 year total shareholder return of 4.56% and 3 year total shareholder return of 192.57% indicate that longer term holders have still seen very large gains despite recent weakness, suggesting sentiment has cooled in the short term even as the broader story remains influenced by expectations around Rezdiffra and MASH treatment demand.
Scan beyond Madrigal Pharmaceuticals and see how other biopharma players with shifting earnings profiles stack up in our hand picked 19 high quality undiscovered gems.
Bulls see a profitable quarter and MASH focus as support for Madrigal Pharmaceuticals’ current valuation. Bears point to recent share price weakness and ongoing losses year to date. Which side does the present pricing tilt toward?
Most Popular Narrative: 36.5% Undervalued
Analysts tracking Madrigal Pharmaceuticals see a fair value of $678.71 compared with the recent $431.16 close, which places the current quote well below that narrative anchor and turns attention to what needs to go right for Rezdiffra over the next decade.
The increasing global prevalence of advanced metabolic and liver diseases, driven by aging populations and lifestyle trends, is expanding the addressable market for Rezdiffra. The company's early-stage penetration (7% of diagnosed U.S. MASH patients) leaves significant room for future patient growth and recurring revenues.
See why 14 investors see Madrigal Pharmaceuticals as 36% undervalued.
Result: Fair Value of $678.71 (UNDERVALUED)
Still, the Madrigal Pharmaceuticals story could be knocked off course if Rezdiffra faces tougher than expected competition, or if reimbursement pressure crimps pricing power.
Find out about the key risks to this Madrigal Pharmaceuticals narrative.
Next Steps
If this mix of optimism and concern around Madrigal Pharmaceuticals feels familiar, that is the point, because every strong thesis has both sides. Move quickly to test the bullish story against your own risk tolerance and expectations for MASH adoption, then weigh the 3 key rewards and 1 important warning sign.
Looking For More Ideas Beyond Madrigal Pharmaceuticals?
If Madrigal Pharmaceuticals has sharpened your focus on opportunity and risk, do not stop here. Use the Simply Wall Street Screener to surface new angles, compare quality, and pressure test your current watchlist against fresh possibilities.
- Target potential mispricing in quality names by scanning the 34 high quality undervalued stocks that match your preferred balance of fundamentals and price.
- Prioritize resilience in uncertain conditions and filter for businesses with stronger finances using the list of solid balance sheet and fundamentals (24 results) before the crowd catches up.
- Zero in on stability seekers’ favorites by reviewing the income focused opportunities flagged in the 4 dividend fortresses and see which payouts warrant a closer look.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com